AKAP13 as A Potential Drug Target for Neurological Disorders (G11214)

Target Name: AKAP13

NCBI ID: G11214

AKAP13

AKAP13 as A Potential Drug Target for Neurological Disorders

AKAP13 (BRX) is a protein that is expressed in the brain and is known for its role in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. It is also known to play a role in the development and progression of certain neurological disorders, such as Alzheimer's disease and Parkinson's disease.

Recent studies have suggested that AKAP13 may be a drug target (or biomarker) for the treatment of these disorders. This is because the protein is known to be involved in the formation of beta-amyloid plaques, which are a hallmark of the development of Alzheimer's disease. Studies have also shown that AKAP13 is involved in the migration of brain cells, which may be a key factor in the progression of certain neurological disorders.

In addition to its potential as a drug target, AKAP13 has also been shown to be a potential biomarker for the diagnosis and progression of certain neurological disorders. For example, studies have shown that levels of AKAP13 are elevated in the brains of individuals with Alzheimer's disease, and that these levels are correlated with the severity of the disease. Similarly, levels of AKAP13 have been shown to be elevated in the brains of individuals with Parkinson's disease, and that these levels are correlated with the severity of the disease.

Overall, the research on AKAP13 suggests that it may be a promising drug target (or biomarker) for the treatment of certain neurological disorders. Further studies are needed to confirm these findings and to determine the best way to use AKAP13 as a therapeutic agent.

Protein Name: A-kinase Anchoring Protein 13

Functions: Scaffold protein that plays an important role in assembling signaling complexes downstream of several types of G protein-coupled receptors. Activates RHOA in response to signaling via G protein-coupled receptors via its function as Rho guanine nucleotide exchange factor (PubMed:11546812, PubMed:15229649, PubMed:23090968, PubMed:25186459, PubMed:24993829). May also activate other Rho family members (PubMed:11546812). Part of a kinase signaling complex that links ADRA1A and ADRA1B adrenergic receptor signaling to the activation of downstream p38 MAP kinases, such as MAPK11 and MAPK14 (PubMed:17537920, PubMed:23716597, PubMed:21224381). Part of a signaling complex that links ADRA1B signaling to the activation of RHOA and IKBKB/IKKB, leading to increased NF-kappa-B transcriptional activity (PubMed:23090968). Part of a RHOA-dependent signaling cascade that mediates responses to lysophosphatidic acid (LPA), a signaling molecule that activates G-protein coupled receptors and potentiates transcriptional activation of the glucocorticoid receptor NR3C1 (PubMed:16469733). Part of a signaling cascade that stimulates MEF2C-dependent gene expression in response to lysophosphatidic acid (LPA) (By similarity). Part of a signaling pathway that activates MAPK11 and/or MAPK14 and leads to increased transcription activation of the estrogen receptors ESR1 and ESR2 (PubMed:9627117, PubMed:11579095). Part of a signaling cascade that links cAMP and EGFR signaling to BRAF signaling and to PKA-mediated phosphorylation of KSR1, leading to the activation of downstream MAP kinases, such as MAPK1 or MAPK3 (PubMed:21102438). Functions as scaffold protein that anchors cAMP-dependent protein kinase (PKA) and PRKD1. This promotes activation of PRKD1, leading to increased phosphorylation of HDAC5 and ultimately cardiomyocyte hypertrophy (By similarity). Has no guanine nucleotide exchange activity on CDC42, Ras or Rac (PubMed:11546812). Required for normal embryonic heart development, and in particular for normal sarcomere formation in the developing cardiomyocytes (By similarity). Plays a role in cardiomyocyte growth and cardiac hypertrophy in response to activation of the beta-adrenergic receptor by phenylephrine or isoproterenol (PubMed:17537920, PubMed:23090968). Required for normal adaptive cardiac hypertrophy in response to pressure overload (PubMed:23716597). Plays a role in osteogenesis (By similarity)

The "AKAP13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AKAP13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets